ATENOLOL Drug Interactions
Also known as: Atenolol
Atenolol is a medication used to treat high blood pressure. It works by helping to relax blood vessels and slow down your heart rate, which lowers your blood pressure and reduces the risk of serious heart problems like strokes and heart attacks.ATENOLOL has 10 documented drug interactions in our database, including 0 contraindicated, 1 major, 2 moderate, and 7 minor interactions.
0
Contraindicated
1
Major
2
Moderate
7
Minor
Concurrent use of atenolol and diltiazem increases the risk of bradycardia, heart block, and hypotension.
Mechanism
Both drugs slow conduction through the AV node and reduce heart rate through complementary mechanisms.
Clinical Management
Monitor heart rate and blood pressure closely. Reduce doses of both agents if combination is necessary.
Combining atenolol and metoprolol tartrate, both beta-blockers, can lead to additive pharmacodynamic effects. This increases the risk of excessive bradycardia, hypotension, and potentially heart block or exacerbation of heart failure symptoms. Patients may experience dizziness, fatigue, or syncope.
Mechanism
Both atenolol and metoprolol tartrate are beta-1 selective adrenergic receptor antagonists. When administered concurrently, their individual beta-blocking effects on the heart are additive, leading to a synergistic reduction in heart rate and blood pressure.
Clinical Management
Concurrent use of two beta-blockers is generally not recommended due to the increased risk of adverse effects without significant additional therapeutic benefit. If combination therapy is deemed necessary, close monitoring of heart rate, blood pressure, and cardiac function is essential. Dosage adjustments of one or both agents may be required, or an alternative antihypertensive or antiarrhythmic agent should be considered.
Concurrent use of ibuprofen with atenolol may reduce the antihypertensive effects of atenolol, potentially leading to elevated blood pressure. This interaction is more pronounced with chronic NSAID use and in patients with pre-existing hypertension or heart failure.
Mechanism
Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis. Prostaglandins play a role in maintaining renal blood flow and sodium excretion, and their inhibition can lead to sodium and fluid retention, which counteracts the blood pressure-lowering effects of atenolol.
Clinical Management
Monitor blood pressure closely when initiating or discontinuing ibuprofen in patients taking atenolol. If blood pressure control is compromised, consider alternative analgesics or increasing the dose of atenolol, if appropriate. Advise patients to use the lowest effective dose of ibuprofen for the shortest duration necessary.
Atenolol and sertraline are generally considered safe to co-administer with a low risk of significant interaction. While both drugs can independently cause bradycardia, atenolol's renal clearance and sertraline's minimal CYP2D6 inhibition suggest a low pharmacokinetic interaction potential.
Mechanism
Atenolol is primarily renally cleared, not significantly metabolized by CYP450 enzymes, thus avoiding pharmacokinetic interaction with sertraline, which has minimal CYP2D6 inhibition. A theoretical additive pharmacodynamic effect leading to bradycardia is possible but generally not clinically significant.
Clinical Management
Routine monitoring for vital signs, especially heart rate, is advisable, particularly when initiating or adjusting doses in sensitive patients. No specific dose adjustments are typically required for either medication due to this combination. If symptomatic bradycardia occurs, consider alternative agents or dose reduction.
The interaction between atenolol and fluoxetine is generally not considered clinically significant due to atenolol's primary renal clearance. Unlike other beta-blockers, atenolol is minimally affected by CYP2D6 inhibition, which is the primary mechanism of interaction for fluoxetine with other beta-blockers.
Mechanism
Fluoxetine is a potent inhibitor of CYP2D6. However, atenolol is primarily eliminated by renal excretion and undergoes minimal hepatic metabolism, including via CYP2D6. Therefore, fluoxetine's inhibitory effect on CYP2D6 has little to no impact on atenolol's pharmacokinetics.
Clinical Management
No specific dose adjustments or enhanced monitoring are typically required when co-administering atenolol and fluoxetine. Clinicians should always monitor patients for expected therapeutic effects and potential side effects of both medications, as with any polypharmacy.
Atenolol and citalopram are unlikely to have a significant pharmacokinetic interaction because atenolol is primarily renally cleared and citalopram has minimal CYP2D6 inhibition. However, both drugs can independently cause bradycardia, so an additive pharmacodynamic effect resulting in mild bradycardia is theoretically possible.
Mechanism
Atenolol is predominantly eliminated renally, bypassing hepatic cytochrome P450 metabolism. Citalopram is a weak inhibitor of CYP2D6, but this is largely irrelevant for atenolol's disposition. Both agents can cause a reduction in heart rate, leading to a potential additive pharmacodynamic effect.
Clinical Management
Generally, no specific dose adjustments are required for this combination. Monitor patients for signs of excessive bradycardia, especially if they have pre-existing cardiac conditions or are on other bradycardia-inducing medications. If bradycardia occurs, consider dose reduction of either agent or alternative therapies.
Atenolol is primarily renally cleared and its metabolism is minimally affected by CYP2D6 inhibition. Therefore, fluoxetine, a potent CYP2D6 inhibitor, is unlikely to cause a significant pharmacokinetic interaction leading to increased atenolol levels. However, both drugs can independently cause bradycardia, so additive pharmacodynamic effects are theoretically possible.
Mechanism
Fluoxetine is a potent inhibitor of CYP2D6. Atenolol is primarily eliminated renally and is not significantly metabolized by CYP2D6, thus its plasma levels are not expected to be significantly altered by fluoxetine. The potential for interaction is primarily pharmacodynamic, as both drugs can cause bradycardia.
Clinical Management
No specific dose adjustments for atenolol are typically required when co-administered with fluoxetine due to a lack of significant pharmacokinetic interaction. Monitor patients for additive bradycardia, especially if they are predisposed to this condition. If bradycardia occurs, consider dose adjustment of either medication or alternative agents.
Atenolol and escitalopram are generally considered safe to co-administer. While both medications can independently cause bradycardia, the risk of a clinically significant additive effect is low due to their primary mechanisms and metabolic pathways.
Mechanism
Atenolol is primarily renally cleared, and escitalopram has minimal CYP2D6 inhibitory activity, thus pharmacokinetic interactions are unlikely. Any potential interaction would be pharmacodynamic, involving additive effects on heart rate, though this is generally not significant.
Clinical Management
Routine monitoring of heart rate and blood pressure is advisable, especially when initiating or adjusting doses of either medication. No specific dose adjustments are typically required for either drug when co-administered. Patients should be advised to report symptoms of excessive bradycardia or hypotension.
The interaction between atenolol and paroxetine is generally considered minor. While paroxetine is a potent CYP2D6 inhibitor, atenolol is primarily renally cleared and not significantly metabolized by CYP2D6, minimizing pharmacokinetic interaction risk. However, both drugs can independently cause bradycardia, so additive pharmacodynamic effects are theoretically possible, though less common with atenolol.
Mechanism
Paroxetine is a potent inhibitor of CYP2D6. However, atenolol is predominantly eliminated by renal excretion of unchanged drug, with minimal hepatic metabolism by CYP2D6. Therefore, paroxetine's CYP2D6 inhibition is unlikely to significantly alter atenolol plasma levels. Both drugs can independently cause bradycardia, suggesting a potential, albeit low, pharmacodynamic additive effect.
Clinical Management
Routine monitoring for signs of excessive beta-blockade (e.g., bradycardia, hypotension) is prudent, especially during initiation or dose changes of either medication, though significant interactions are rare. No specific dose adjustments are typically required for atenolol when co-administered with paroxetine. If excessive bradycardia or hypotension occurs, consider alternative beta-blockers that are also renally cleared or SSRIs with less CYP2D6 inhibition.
Atenolol is primarily renally cleared and not significantly metabolized by cytochrome P450 enzymes, including those inhibited by fluvoxamine. Therefore, a significant pharmacokinetic interaction is unlikely. However, both drugs can independently cause bradycardia, so additive pharmacodynamic effects are theoretically possible, though generally not clinically significant with atenolol.
Mechanism
Atenolol is eliminated largely unchanged by the kidneys, with minimal hepatic metabolism. Fluvoxamine is a potent inhibitor of CYP1A2 and CYP2C19, but these enzymes are not primary pathways for atenolol metabolism.
Clinical Management
No specific dose adjustments are typically required for atenolol when co-administered with fluvoxamine due to the lack of significant pharmacokinetic interaction. Monitor for additive pharmacodynamic effects such as excessive bradycardia or hypotension, especially in sensitive patients, although this is rare given atenolol's elimination profile.
For complete prescribing information:
View full ATENOLOL monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.